新疆百花村医药集团股份有限公司 一、 召开会议的基本情况 (一) 股东大会类型和届次 证券代码：600721 证券简称：百花医药 公告编号：2025-033 新疆百花村医药集团股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东大会召开日期：2025年9月8日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 2025年第一次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 8 日 12 点 00 分 召开地点：新疆百花村医药集团股份有限公司 22 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 8 日 至2025 年 9 月 8 日 上述议案已经公司第九届董事会第六次会议审议通过， ...

新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 第九届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会召开情况 新疆百花村医药集团股份有限公司（以下简称"公司"）第九届监事会第五 次会议，于 2025 年 8 月 20 日北京时间 13:00，在公司 22 楼会议室以现场结合通 讯方式召开。本次会议以电子邮件的方式发出会议通知。应参会监事 3 人，实际 参会监事 3 人，公司相关人员列席了会议。会议由监事会主席马斌先生主持，会 议符合《公司法》和《公司章程》的规定，会议召开有效，公司相关人员列席本 次会议。 二、监事会会议审议情况 1.审议通过《公司 2025 年半年度报告全文及摘要》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 监事会经认真审核公司 2025 年半年度报告全文及摘要后认为： （1）半年度报告的编制和审议程序符合法律法规、《公司章程》及公司内 部管理制度的各项规定。 证券代码：600721 证券简称：百花医药 公告编号：2025-028 表决结果：同 ...

新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 第九届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 新疆百花村医药集团股份有限公司（以下简称"公司"）第九届董事会第六 次会议，于 2025 年 8 月 20 日北京时间 11:30，在公司 22 楼会议室以现场结合通 讯方式召开。本次会议以电子邮件的方式发出会议通知。应参会董事 10 人，实 际参会董事 10 人。会议由董事长郑彩红女士主持，会议符合《公司法》和《公 司章程》的规定，会议召开有效，公司监事、高管列席本次会议。 二、董事会会议审议情况 证券代码：600721 证券简称：百花医药 编号：2025-027 1.审议通过《公司 2025 年半年度报告全文及摘要》 表决结果：同意 10 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会审议通过。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）《公司 2025 年半年度报告》。 2.审议通过《公司关于取消监事会、修订 ...

Core Viewpoint - Baihua Pharmaceutical reported a year-on-year increase in revenue and net profit for the first half of 2025, indicating stable growth in its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 202 million yuan, representing a year-on-year increase of 2.95% [2] - The net profit attributable to shareholders was around 25.48 million yuan, reflecting a year-on-year increase of 12.45% [2] - Basic earnings per share were 0.0663 yuan, which is an increase of 11.62% compared to the previous year [2]

新疆百花村医药集团股份有限公司 公司代码：600721 公司简称：百花医药 新疆百花村医药集团股份有限公司 2025 年半年度报告 1 / 151 新疆百花村医药集团股份有限公司 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人郑彩红、主管会计工作负责人蔡子云及会计机构负责人（会计主管人员） 余涛 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 □适用 √不适用 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 无 十一、 其他 | 第一节 | 释义 | 4 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指 ...

Core Viewpoint - The company reported a revenue of 202 million yuan for the first half of 2025, reflecting a year-on-year growth of 2.95% and a net profit of 25.48 million yuan, which represents a year-on-year increase of 12.45% [1] Financial Performance - Revenue for the first half of 2025 reached 202 million yuan, marking a 2.95% increase compared to the previous year [1] - Net profit for the same period was 25.48 million yuan, showing a growth of 12.45% year-on-year [1]

Core Insights - The healthcare services sector experienced a rise of 1.26% on August 18, with a net outflow of 1.405 billion yuan in principal funds [1] - Among the constituent stocks, 33 increased in value while 9 decreased [1] Fund Flow Analysis - The top net outflows were recorded for WuXi AppTec at 478 million yuan, Innovent Biologics at 410 million yuan, and Kelun Pharmaceutical at 175 million yuan [1] - Other notable outflows included Sanbo Brain Science at 157 million yuan and Ruizhi Pharmaceutical at 54.73 million yuan [1] Stock Performance - Key stocks with significant performance included: - Kanglong Chemical with a price of 30.94 and an increase of 2.35%, attracting a net inflow of 68.68 million yuan [1] - Baihua Pharmaceutical at 8.78, up 10.03%, with a net inflow of 63.97 million yuan [1] - Aier Eye Hospital at 13.22, up 1.34%, with a net inflow of 784.89 thousand yuan [1] - Huakang Clean at 33.28, up 13.39%, with a net inflow of 3316.13 thousand yuan [1] - Tongce Medical at 46.18, up 2.26%, with a net inflow of 3071.04 thousand yuan [1]

Group 1 - The core point of the article is that the FDA has accelerated the approval of Wegovy (2.4 mg semaglutide) for treating moderate to severe liver fibrosis in adult patients with non-alcoholic steatohepatitis (NASH), leading to significant stock price increases for several pharmaceutical companies [1] Group 2 - Hanyu Pharmaceutical's stock rose over 10% following the news [1] - Companies such as Sunlight Novo and Jinkai Biotechnology saw stock increases of over 5% [1] - Novo Nordisk's stock rose over 6% in after-hours trading in the US market due to the FDA announcement [1]

Group 1 - The core viewpoint of the news is that Baihua Pharmaceutical (600721) has shown a slight decline in stock price and has experienced significant net outflow of funds, indicating potential investor concerns [1] - As of August 5, 2025, Baihua Pharmaceutical's stock closed at 8.2 yuan, down 0.85%, with a turnover rate of 4.61% and a trading volume of 177,200 hands, amounting to 146 million yuan [1] - The latest financial performance for Baihua Pharmaceutical shows total revenue of 96.91 million yuan for Q1 2025, a year-on-year increase of 6.65%, while net profit attributable to shareholders was 20.72 million yuan, up 0.28% year-on-year [1] Group 2 - The company has a current liquidity ratio of 1.979, a quick ratio of 1.624, and a debt-to-asset ratio of 30.45%, indicating a stable financial position [1] - Baihua Pharmaceutical has made investments in 12 external companies and participated in 16 bidding projects, showcasing its active engagement in business expansion [2] - The company holds 16 trademark registrations and has obtained 6 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Baihua Pharmaceutical, indicating a positive trend in revenue and net profit growth [1] - As of July 30, 2025, Baihua Pharmaceutical's stock closed at 8.48 yuan, reflecting a 2.17% increase with a turnover rate of 12.58% and a trading volume of 483,300 hands, amounting to a transaction value of 409 million yuan [1] - The company reported total operating revenue of 96.91 million yuan for Q1 2025, representing a year-on-year growth of 6.65%, while the net profit attributable to shareholders was 20.72 million yuan, up 0.28% year-on-year [1] Group 2 - Baihua Pharmaceutical has a current liquidity ratio of 1.979 and a quick ratio of 1.624, indicating a strong short-term financial position, with a debt-to-asset ratio of 30.45% [1] - The company has made investments in 12 enterprises and participated in 16 bidding projects, showcasing its active engagement in business expansion [2] - Baihua Pharmaceutical holds 16 trademark registrations and has obtained 6 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]